Valneva SEWBO:VLA +0.63%58 Gross Margin % is 15.28% as of Mar. 2026, which is 68% below its 10-year median of 48.40. GuruFocus rates WBO:VLA with a GF Score™ of 58/100 and a GF Value™ of €2.49 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 735 Biotechnology companies, Valneva SE ranks worse than 76.46% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Valneva SE's Gross Profit for the
three
months ended in Mar. 2026 was €4.7 Mil. Valneva SE's Revenue for the
three
months ended in Mar. 2026 was €30.9 Mil. Therefore, Valneva SE's Gross Margin % for the quarter that ended in Mar. 2026 was 15.28%.
Warning Sign:
Valneva SE gross margin has been in long-term decline. The average rate of decline per year is -1.2%.
The historical rank and industry rank for Valneva SE's Gross Margin % or its related term are showing as below:
WBO:VLA'
s Gross Margin % Range Over the Past 10 Years
Min: 10.2 Med: 48.4 Max: 60.68
Current: 29.46
During the past 13 years, the highestGross Margin % of Valneva SE was 60.68%. The lowest was 10.20%. And the median was 48.40%.
WBO:VLA's Gross Margin % is ranked worse than 76.46% of 735
companies
in the Biotechnology industry
Industry Median: 60.9
vs WBO:VLA: 29.46
Valneva SE had a gross margin of 15.28% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Valneva SE was -1.20% per year.
Valneva SE (WBO:VLA) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Valneva SE had a gross margin of 15.28% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Valneva SE Gross Margin % Related Terms
Valneva SE Gross Margin % Historical Data
* Premium members only.
The historical data trend for Valneva SE's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:VLA vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Valneva SE's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valneva SE Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valneva SE's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Valneva SE's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Valneva SE (WBO:VLA) has a Gross Margin % of 15.28% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Valneva SE and its competitors. This is 68% below median its historical median of 48.40. Over the past decade, Valneva SE's Gross Margin % has ranged from 10.20 to 60.68. According to the industry distribution chart, Valneva SE ranks #562 out of 735 companies in the Biotechnology industry, placing it in the top 76.5%.
Is Valneva SE's Gross Margin % too high?
Valneva SE's current Gross Margin % of 15.28% is 68% below median its 10-year median of 48.40. Over the past 10 years, this metric has ranged from a low of 10.20 to a high of 60.68. The Biotechnology industry median Gross Margin % is 60.90. Valneva SE's value of 15.28% is 74.9% below this industry median. Based on the distribution chart, Valneva SE ranks #562 out of 735 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Valneva SE has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valneva SE ranks #562 out of 735 companies for Gross Margin %. This places Valneva SE in the lower half of its industry. The industry median Gross Margin % is 60.90. Valneva SE's value of 15.28% is 74.9% below this benchmark. Historically, Valneva SE's own Gross Margin % has ranged from 10.20 to 60.68 over the past decade. While the company's 10-year median is 48.40 vs. the industry median of 60.90, Valneva SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valneva SE's current Gross Margin % of 15.28% is 74.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Valneva SE and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valneva SE's current Gross Margin % is 15.28%, which is 68% below median its own 10-year median of 48.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (WBO:VLA) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.49, compared to a current price of €2.24 — trading 9.9% below its estimated fair value. The current Gross Margin % is 15.28%, which is 68% below median its 10-year median of 48.40 and 74.9% below the Biotechnology industry median of 60.90. Valneva SE's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Valneva SE (WBO:VLA), the current Gross Margin % is 15.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valneva SE (WBO:VLA) Overvalued in 2026?
Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued.
The current stock price of €2.24 is trading 9.9% below its estimated GF Value™ of €2.49.
GuruFocus considers Valneva SE to be Modestly Undervalued.
Key valuation signals for WBO:VLA:
Gross Margin %: 15.28% (68% below median its 10-year median of 48.40)
GF Value™: €2.49 vs. price of €2.24 (9.9% below fair value)
Industry Position: 74.9% below the Biotechnology median (#562 of 735)
No single metric tells the full story. See the WBO:VLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
58GF Score
Get the complete analysis for WBO:VLA
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:VLA has been successfully added to your 
